企業プロフィール
Alnylam Pharmaceuticals, Inc. 株価・ニュース・カタリスト
- ティッカー:
- ALNY
- 取引所:
- NASDAQ
- セクター:
- Nucleic Acid Drugs
- 所在地:
- Cambridge, Massachusetts
株価パフォーマンス
231.18 USD (-6.31%)
終値
最終更新: 2026年10月1日
38.2B USD
時価総額
株価変動の要因
2026年10月1日 時点で ALNY は 6.31% 下落し、$231.18 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
RNA Interference Therapeutics Leader
Alnylam Pharmaceuticals develops medicines that use RNA interference to silence disease-causing genes. Its platform is designed to achieve durable reduction of specific proteins through infrequent subcutaneous or intravenous dosing, with programs spanning rare, cardiometabolic, and neurological diseases.
Transthyretin Amyloidosis Franchise
The company's largest franchise is built around AMVUTTRA and ONPATTRO for transthyretin-mediated amyloidosis. AMVUTTRA is positioned across both polyneuropathy and cardiomyopathy manifestations of ATTR, giving Alnylam a broad commercial presence in a progressive systemic disease.
Commercial Rare-Disease Portfolio
Alnylam also markets GIVLAARI for acute hepatic porphyria and OXLUMO for primary hyperoxaluria type 1. These products demonstrate the platform's ability to address liver-expressed genetic targets and support a specialized commercial model centered on diagnosis, patient identification, and long-term treatment.
Partnered Medicines and Economics
The company receives royalties from partnered RNAi medicines, including Leqvio, and collaborates with large pharmaceutical companies on development programs such as zilebesiran for hypertension. This structure allows Alnylam to retain selected products while using partners to reach broader primary-care and global markets.
Expanding Pipeline Beyond the Liver
Pipeline programs include ALN-6400 for bleeding disorders, mivelsiran for neurological disease, ALN-HTT02 for Huntington's disease, and ALN-2232 for obesity and weight management. New delivery approaches are intended to extend RNAi into the central nervous system and other tissues beyond the liver.
今後のカタリスト
- Presentation of Phase 1 ALN-HTT02 data in Huntington's disease at the 2026 European Huntington's Disease Network meeting.
- Phase 1 clinical results for ALN-6400 in healthy volunteers during 2026.
- Phase 1 clinical results for ALN-2232 in obesity and weight management during 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。